Cooley, Davis Polk Steer Biotech Firm's Upsized $540M IPO
Immunology-focused drug developer Acelyrin Inc. priced an upsized $540 million initial public offering on Thursday, the largest biotechnology IPO this year, represented by Cooley LLP and underwriters counsel Davis Polk &...To view the full article, register now.
Already a subscriber? Click here to view full article